Jingjing Pharmaceutical Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and sales of high-quality APIs, intermediates, and amino acid series products. Founded in October 2007, the company covers an area of 310 mu, with a registered capital of 257.28 million yuan. We have established technical platforms such as national-local joint laboratories and academician workstations, and own 62 patents, including 39 invention patents.
Over the years, the company has consistently focused on professional customization capabilities, quality improvement capabilities, process innovation capabilities, and industrial incubation capabilities. Leveraging our technical advantages in biosynthesis (microbial fermentation, biocatalysis), chemical synthesis, and crystallization control, we have gradually formed two major business segments: First, adhering to the product concept of "quality excellence," we provide customers with high-tech value-added specialty APIs and pharmaceutical intermediates, actively practicing the cooperation service concept of "meeting needs and exceeding expectations." We have gradually accumulated a group of like-minded partners and further expanded diversified cooperation methods and development models to establish long-term strategic partnerships. Second, we have successfully applied efficient biocatalysis technology in the industrialization of some amino acids and their derivatives, achieving globally leading levels in product cost and quality, with obvious competitive advantages.
"Originating from life, revering life, and protecting life" is the mission of Jingjing people, while "being China's pharmaceutical professionals" and "manufacturing reliable medicines with dedication" are our commitments. In the new era and new starting point, the company actively embraces new challenges and goals. We have established our 2023-2027 five-year development plan: accelerating the IPO process, combining industry and finance, helping the enterprise accelerate strategic transformation, striving to achieve product structure transformation by 2027, forming a development pattern of east and west plant asset linkage and upstream-downstream product association, growing into a specialty API manufacturer with revenue exceeding 1 billion yuan. During this process, we aim to achieve the goals of "cultivating a team of middle-level managers who share the same values, have fighting spirit, and can take responsibility" and "developing a group of strategic partners with aligned values."
"Excellence through unity, crystallizing together," we will continue to root ourselves in the biopharmaceutical industry, carrying out diversified cooperation with numerous partners, complementing advantages, and jointly helping to improve the quality of life! Jingjing wishes to join hands with you to create unlimited possibilities for the future!
